North China Pharmaceuticals to enter market for recombinant human serum albumin production

After more than 10 years of development, NCPC is reported to have achieved a high-purity rHSA production technology which will soon enter the market. The product and its production is covered by over 20 patents and production patents in 13 countries.

China Bioindustry Industrial Network, January 24, 2014

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year. Accept or Deny